Jacob Johnson
Stock Analyst at Stephens & Co.
(2.85)
# 1,610
Out of 5,139 analysts
78
Total ratings
45.76%
Success rate
8.57%
Average return
Main Sectors:
Stocks Rated by Jacob Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STE STERIS | Reiterates: Overweight | $240 | $251.18 | -4.45% | 7 | Feb 6, 2025 | |
| MASS 908 Devices | Reiterates: Overweight | $6 | $6.99 | -14.16% | 4 | Jan 15, 2025 | |
| LFCR Lifecore Biomedical | Reiterates: Equal-Weight | $6 | $7.20 | -16.67% | 5 | Jan 3, 2025 | |
| AZTA Azenta | Reiterates: Overweight | $60 | $29.67 | +102.22% | 6 | Jan 2, 2025 | |
| DHR Danaher | Reiterates: Overweight | $315 | $211.25 | +49.11% | 2 | Oct 23, 2024 | |
| TMO Thermo Fisher Scientific | Initiates: Overweight | $680 | $515.12 | +32.01% | 1 | Oct 1, 2024 | |
| RGEN Repligen | Reiterates: Overweight | $170 | $137.22 | +23.89% | 4 | Jul 30, 2024 | |
| TKNO Alpha Teknova | Reiterates: Overweight | $5 | $2.09 | +139.23% | 5 | Jul 10, 2024 | |
| MXCT MaxCyte | Reiterates: Overweight | $11 | $0.73 | +1,401.50% | 5 | Apr 23, 2024 | |
| STVN Stevanato Group | Reiterates: Overweight | $38 | $16.30 | +133.13% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $8.67 | +96.08% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.5 | $2.56 | -2.34% | 3 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $87 | $58.25 | +49.36% | 10 | Feb 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $390 | $243.83 | +59.95% | 8 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $16 → $18 | $10.01 | +79.82% | 5 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.18 | +408.47% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $29 | $23.23 | +24.84% | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $153 → $130 | $186.32 | -30.23% | 2 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $377 | $164.24 | +129.54% | 1 | Apr 7, 2022 |
STERIS
Feb 6, 2025
Reiterates: Overweight
Price Target: $240
Current: $251.18
Upside: -4.45%
908 Devices
Jan 15, 2025
Reiterates: Overweight
Price Target: $6
Current: $6.99
Upside: -14.16%
Lifecore Biomedical
Jan 3, 2025
Reiterates: Equal-Weight
Price Target: $6
Current: $7.20
Upside: -16.67%
Azenta
Jan 2, 2025
Reiterates: Overweight
Price Target: $60
Current: $29.67
Upside: +102.22%
Danaher
Oct 23, 2024
Reiterates: Overweight
Price Target: $315
Current: $211.25
Upside: +49.11%
Thermo Fisher Scientific
Oct 1, 2024
Initiates: Overweight
Price Target: $680
Current: $515.12
Upside: +32.01%
Repligen
Jul 30, 2024
Reiterates: Overweight
Price Target: $170
Current: $137.22
Upside: +23.89%
Alpha Teknova
Jul 10, 2024
Reiterates: Overweight
Price Target: $5
Current: $2.09
Upside: +139.23%
MaxCyte
Apr 23, 2024
Reiterates: Overweight
Price Target: $11
Current: $0.73
Upside: +1,401.50%
Stevanato Group
Mar 25, 2024
Reiterates: Overweight
Price Target: $38
Current: $16.30
Upside: +133.13%
Mar 13, 2024
Reiterates: Equal-Weight
Price Target: $17
Current: $8.67
Upside: +96.08%
Mar 7, 2024
Reiterates: Equal-Weight
Price Target: $2.5
Current: $2.56
Upside: -2.34%
Feb 2, 2024
Maintains: Overweight
Price Target: $92 → $87
Current: $58.25
Upside: +49.36%
Oct 27, 2023
Maintains: Overweight
Price Target: $420 → $390
Current: $243.83
Upside: +59.95%
Aug 21, 2023
Upgrades: Overweight
Price Target: $16 → $18
Current: $10.01
Upside: +79.82%
Jul 21, 2023
Reiterates: Overweight
Price Target: $6
Current: $1.18
Upside: +408.47%
Jul 17, 2023
Maintains: Overweight
Price Target: $27 → $29
Current: $23.23
Upside: +24.84%
May 16, 2022
Maintains: Overweight
Price Target: $153 → $130
Current: $186.32
Upside: -30.23%
Apr 7, 2022
Initiates: Overweight
Price Target: $377
Current: $164.24
Upside: +129.54%